Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.
Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T, Daud AI, McCalmont TH, LeBoit PE, Ortiz-Urda S.
Posch C, et al. Among authors: leboit pe.
Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4015-20. doi: 10.1073/pnas.1216013110. Epub 2013 Feb 19.
Proc Natl Acad Sci U S A. 2013.
PMID: 23431193
Free PMC article.